Kornimate/medical-research-clean huggingface dataset:
manual dexterity in ulnar styloid fracture patients

Conditions: Ulnar Styloid Fracture; Distal Radius Fracture

Summary: fracture of the distal radius (drf) is a common musculoskeletal system injury. fracture of the ulnar styloid frequently accompanies fractures of the distal radius and is seen in 50-65% of these cases. the loss of dexterity is common in many musculoskeletal conditions. the aim of this study was to investigate whether an associated ulnar styloid fracture following a distal radius fracture has any effect on manual dexterity. patients who diagnosed with isolated drf or drf accompanied with ulnar styloid fracture and applied to hand rehabilitation unit were included in the study. the patients were divided into two groups according to the ulnar styloid fracture presence. usf group was drf with ulnar styloid fracture; non-usf group was drf without ulnar styloid fracture. pain, range of motion, quick-dash, hand grip and pinch strength, purdue pegboard test, jebsen taylor hand function test was measured at six month. a total of 125 patients, 68 female (54,4%) and 57 male (45,6%) were included in the study. the mean age of the patients was 47,15±13,41 (18-65) years. 65 of the patients (52%) had isolated fracture of the distal radius fracture (non-usf group) and 60 patients (48%) had a concurrent ulnar styloid fracture (usf group). there was no significant difference in pain between the groups (p\>0,05). joints range of motion were higher in the non-usf group than in the usf group. this difference was statistically significant only for flexion and extension (p\ 0,05). the injured hand grip and pinch strength values in non-usf group were greater than the usf group but the difference was not statistically significant (p\>0,05). the manual dexterity and hand function tests showed that there was no statistically significant difference between the groups at six months (p\>0,05). there is a consensus that ulnar styloid fracture has no effect on overall hand function. but, there is no study dwelled on the manual dexterity. in this study, the effect of ulnar styloid fracture on hand function is more clearly emphasized. in conclusion, concomitant usf does not lead poorer manual dexterity.


Eligibility criteria:
inclusion criteria: * the criteria for inclusion in this prospective cohort study were; 1) aged between 18 and 60 years, 2) diagnosed with isolated drf or drf accompanied with ulnar styloid fracture, 3) primarily fixation after injury exclusion criteria: * exclusion criteria were; 1)radius shaft, ulnar head or ulnar shaft fractures, 2) pre-existing rheumatological diseases associated with ipsilateral extremity, 3) comorbid injuries such as tendon or nerve injuries, 4) coexisting distal radioulnar, radiocarpal or ulnocarpal joint instability problems, 5) secondarily repair.

Keywords: distal radius fracture ulnar styloid fracture manual dexterity
safety and efficacy of gpoem in the treatment of gastroparesis

Conditions: Gastroparesis; Gastroparesis Postoperative; Gastroparesis With Diabetes Mellitus

Summary: the purpose of this study is to assess the clinical efficacy and safety in the treatment of gastroparesis.

after being informed about the data collected, all the patients affected with gastroparesis undergoing gastric per-oral endoscopic myotomy (gpoem) will be included in the observational protocol. data concerning pre-operative symptoms and results of the imaging studies will be recorded together with operative time and operative complications. patients will undergo periodical clinical consults and gastric emptying scintigraphy to assess the improvement in the symptoms and gastric motility.

Eligibility criteria:
inclusion criteria: * gastroparesis (gcsi \> 2 or gastric emptying half-time \> 180 min or gastric retention at 120 min \> 60% or good response to botulinum if former criteria not met) exclusion criteria: * age \< 18 years * inability to understand protocol

Keywords: gpoem gastroparesis pyloromyotomy
enhancing exposure therapy for snake and spider phobias

Conditions: Specific Phobia

Summary: this study tests whether exposure therapy for fear of snakes or spiders is enhanced by the addition of a brief fear retrieval trial prior to treatment, and the use of compound extinction during treatment. the goal of the study is to determine whether these behavioral techniques enhance the efficacy of exposure therapy, one of the most empirically supported treatments for anxiety disorders.

this study tests whether exposure therapy for fear of snakes or spiders is enhanced by the addition of a brief fear retrieval trial prior to treatment, and the use of compound extinction during treatment. the goal of the study is to determine whether these behavioral techniques enhance the efficacy of exposure therapy, one of the most empirically supported treatments for anxiety disorders. individuals between the ages of 18-65 with elevated fear of spiders or fear of snakes are randomly assigned to one of four treatment conditions (1) standard exposure therapy, (2) exposure therapy with fear retrieval augmentation, (3) exposure therapy with compound extinction augmentation, and (4) exposure therapy with fear retrieval and compound extinction augmentations. all participants undergo an online prescreen and a face-to-face screening assessment to determine eligibility and baseline (pre-treatment) symptom severity. participants additionally complete assessments directly after treatment (post-treatment), and approximately one week after treatment (follow-up). the pre-treatment assessment occurs 1-14 days prior to treatment, the post-treatment assessment occurs during the treatment visit as soon as the treatment procedure is complete, and the follow-up assessment occurs within a window of 6-14 days after the completion of treatment. participants complete two behavioral approach tests (in the treatment context and in the generalization context) at pre-treatment, post-treatment, and follow-up. participants complete a battery of self-report questionnaires at pre-treatment and follow-up.

Eligibility criteria:
inclusion criteria: 1. age 18 to 65. 2. speaks english fluently. 3. a score of 70 or higher on the fear of snakes/spiders questionnaire. 4. demonstrates avoidance during behavioral approach tests (defined as inability to put palm flat on the bottom of a tank containing a snake/spider, and inability to touch a snake/spider with a bare finger). exclusion criteria: 1. unstable dose of psychotropic medications during the 4 weeks prior to baseline assessment. 2. currently receiving exposure-based treatment for snake/spider phobia. 3. currently at risk for suicide.
sildenafil for prevention of cerebral vasospasm

Conditions: Subarachnoid Hemorrhage; Cerebral Vasospasm; Rupture of Intracranial Aneurysm

Summary: a randomized clinical trial with security and dose testing of sildenafil citrate in patients with subarachnoid hemorrhage due to a rupture of a cerebral aneurism for prevention of cerebral vasospasm. the cerebral vasospasm is a decrease in blood flow that occurs when the intracranial vessels lose their capability of self-control of dilations and contractions. patients with subarachnoid hemorrhage without neurological deficits who underwent endovascular or surgical correction of the aneurysm can participate in this trial. they will be randomized to a daily doses of 75 mg of sildenafil, 150 mg of sildenafil or placebo from the third to the 14th day post bleeding. today there is no proven clinical treatment for prevention of cerebral vasospasm.


Eligibility criteria:
inclusion criteria: * males and females between 20 and 80 years old * subarachnoid hemorrhage confirmed by ct with fisher iii or iv criteria (blood in cisterns larger than 1 mm with or without blood in the ventricular system). * aneurysm detected in the conventional angiography, or angio-ct or angio - mri. * patient underwent surgery for clipping or endovascular treatment in the first 72 hours after the ictus. * consent form signed by the patient or legal responsible. exclusion criteria: * patient (or legal responsible) refuses to participate. * impossibility to collect consent form. * hemodynamical instability. * previous cardiac ischemic disease. * history of cardiac arrhythmia within the last 6 months. * history of retinitis pigmentosa. * previous use of drugs witch can interact with sildenafil (specially nitrates). * pregnancy. * known hypersensibility to sildenafil.

Keywords: aneurysm vasospasm sildenafil viagra
aida 2000 guidelines

Conditions: Acute Promyelocytic Leukemia

Summary: prospective use of rt-pcr for pml/rara might be used to guide a total tehrapy approach in apl, including refined diagnosis, front-line treatment, assessment of response and anticipated salvage therapy for patients who undergo molecular relapse.


Eligibility criteria:
inclusion criteria: * age \>= 1 years and \< 61 years * morphologic diagnosis of apl * ps \<= 3 * presence in leukemic cells at diagnosis of t(15;17), and/or pml/rara rearrangement by rt-pcr. t * the presence of additional cytogenetic lesions is not considered an exclusion criterion * serum creatinine \<=2.5 mg/dl * serum bilirubin, alkaline phosphatase, or got/asat \<= 3 times the upper normal limit * negative pregnancy test * written informed consent exclusion criteria: * age \>= 61 years * prior antileukemic chemotherapy for apl * absence of pml-rara rearrangement after successful rna extraction and amplification of control gene * prior antileikemic chemotherapy for apl * presence of a concomitant malignant neoplasm, except basal cell carcinoma concurrent treatment with cytotoxic chemotherapy or radiotherapy * oteher progressive malignant disease. however, secondary acute promyelocytic leukemia following "cured" hodgkin's disease or otehr cured malignancies may be included, as well as secondary leukemias following other exposure to alkylating agents or radiation for other reasons

Keywords: acute promyelocytic leukemia apl
study of telintra for treatment of chemotherapy induced neutropenia in patients with non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: tlk199.2102 was a multicenter phase 2 randomized study to determine the effect of telintra treatment on chemotherapy induced neutropenia (cin) in patients with non small cell lung cancer receiving first-line therapy with carboplatin and docetaxel.

tlk199.2102 was a multicenter phase 2 randomized study to determine the effect of telintra treatment on chemotherapy induced neutropenia (cin) in patients with non small cell lung cancer receiving first-line therapy with carboplatin and docetaxel. after randomization, patients in treatment arm 1, chemotherapy with carboplatin and docetaxel will be administered on day 1 of each cycle, followed by telintra at a starting dose of 3000 mg total daily dose (1500 mg orally, twice daily) on day 2 until the absolute neutrophil count improves as confirmed by two consecutive measurement at least 24 hours apart. in treatment arm 2 (control arm), chemotherapy alone consisting of carboplatin and docetaxel will be administered on day 1 of each cycle.

Eligibility criteria:
inclusion criteria: * histologically confirmed nsclc * stage iiib-stage iv nsclc * ecog performance status of 0-2 * adequate liver and renal function * adequate bone marrow reserve exclusion criteria: * treatment with neoadjuvant or adjuvant chemotherapy within 1 year * histologically confirmed mixed tumors containing small cell elements * treatment with radiotherapy (except limited in nature) within 3 weeks of randomization * history of bone marrow transplantation or stem cell support * known history of cns metastasis unless the patient has had treatment with surgery or radiotherapy, is neurologically stable and does not require oral or iv steroids or anticonvulsants * history of hiv * grade 3 or 4 peripheral neuropathy * weightloss greater than 5% within 6 months * uncontrolled pleural effusion

Keywords: nsclc chemotherapy induced neutropenia cin
developmental language difficulties: behavioural and electrophysiological studies

Conditions: Dyslexia; Dysphasia

Summary: this study will help to better characterize oral and written language disorders and determine if these disorders are continuous or not. the participants ( dyslexic and dysphasic patients and control adults) will carry out an auditory lexical decision task during which an electroencephalogram (eeg) will be recorded.


Eligibility criteria:
inclusion criteria (patients): * non-verbal intelligence quotient (iq) less than 85 according to the wechsler intelligence scale for children (wisc) perceptual index * specific oral language disorders diagnosed by the multidisciplinary team (neurologist, psychologist, speech therapist): understanding language deficit, estimated by the test scotland (lecocq, 1996) and / or vocabulary test (dunn thiébaud). * specific written language disorders (dyslexia) diagnosed by a multidisciplinary team according to a test that can objectify the late reading (alouette) and locate deficits (evalec) * be affiliated to a social security regimen * have signed an informed consent or signed by the parents if the patient is minor * aged at least 8 years old inclusion criteria (controls) * non-deficit (\>85) non-verbal wechsler scale (codes and matrices) * no specific oral language disorders * no specific written language disorders (dyslexia) * be affiliated to a social security regimen * have signed an informed consent or signed by the parents if the patient is minor * aged at least 8 years old exclusion criteria: * mother tongue other than french * non-verbal reasoning abilities below 85 measured by the wisc 4 (for patients only) and non-verbal capacities of reasoning lower than the normal measured by the non-verbal scale of wechsler (for controls only) * presence of pervasive developmental disorders * no affiliation to a social security regimen * absence of signature of the informed consent * subject of less than 8 years

Keywords: language disorders developmental disorders of oral and written language
improved pain management in knee osteoarthritis-related surgeries

Conditions: Knee Osteoarthritis; Total Knee Arthroplasty; Unicompartmental Knee Arthroplasty; High Tibial Osteotomy; Pain Management

Summary: in recent years, pain management coordinated with enhanced recovery after surgery (eras) has been widely applied and rapidly developed in orthopedics, showing promising prospects. since 2016, our hospital has used a series of continuously improved pain management schemes for patients with knee oa who underwent total knee arthroplasty (tka), unicompartmental knee arthroplasty (uka), and high tibial osteotomy (hto). here, we retrospectively analyze these patients' clinical data to compare the effects of different pain intervention measures during the perioperative period on postoperative pain, functional exercise, hospital stay, and prognosis of the three surgical methods in an attempt to provide a feasible solution for pain management of these patients.

we retrospectively analyzed the clinical data of patients with knee osteoarthritis (oa) who received surgical treatment to provide a feasible solution for perioperative pain management of these patients. the medical records of 714 patients with knee oa who had undergone total knee arthroplasty (n=551), unicompartmental knee arthroplasty (n=92) and high tibial osteotomy (n=71) were retrospectively analyzed and the cases were divided into groups a, b, and c, according to the continuously optimized pain management. clinical data including anesthesia grade, surgery time, functional exercise, hospital stay, pain, emotion, complications and prognosis were compared.

Eligibility criteria:
inclusion criteria: * first knee surgery were 50-80 years old had complete clinical and follow-up data exclusion criteria: * american society of anesthesiologists physical status grade≥4 comorbidity with three or more systemic diseases long-term anxiety and depression, contraindications of painkillers, long-term alcoholism, or taking painkillers concomitant limb pain caused by spinal degeneration
botswana combination prevention project

Conditions: HIV

Summary: the bcpp study is designed to test the hypothesis that implementing an enhanced combination prevention package which includes provision of art to all participants, regardless of cd4 count or hiv disease severity, will impact the hiv/aids epidemic by significantly reducing population-level, cumulative hiv incidence in a defined geographic area over a period of 3 years and will be cost-effective.


Eligibility criteria:
inclusion criteria: * protocol #1 - baseline household survey (bhs): permanent or part-time study community resident in any of the 30 study communities; botswana citizen or spouse of a botswana citizen; able to provide informed consent if ≥18 years old, or able to provide assent to complement a guardian's permission, if a minor (aged 16 or 17). * protocol #3 - expanded treatment cohort: hiv-infected persons in combination prevention communities who are not yet on art and are able to provide informed consent if ≥18 years old, or able to provide assent to complement a guardian's permission, if a minor (aged 16 or 17). exclusion criteria: * persons who do not meet inclusion criteria.
pediatric quality of life among population with body mass index (bmi) greater than or equal to 85%

Conditions: Pediatric Obesity

Summary: we are currently experiencing an epidemic of obesity in the pediatric population. this epidemic affects many areas including quality of life. we have been conducting a nutrition and exercise program since 2003. we have noticed that many of the participants seem to have a better quality of life after finishing the one year program compared to when they started. we would like to objectively quantify this improvement using a validated questionnaire at the beginning and at the end of the study. questionnaires will be given to participants and to their caretakers at the same time. there will be two groups in the study: one intervention (minimum attendance of 4 sessions) and one control group.

we are currently experiencing an obesity epidemic in the pediatric population. the latest national health and nutrition examination survey (nhanes) data indicates that 16.5% has a bmi greater than or equal to 85% \< 95% and 17.1% has a bmi greater than or equal to 95%. the quality of life of children who are obese has been shown to be lower than that of children with cancer. health related quality of life measurements have emerged as an important health outcome in clinical trials, clinical practice improvement strategies, and healthcare services research and evaluation. we have conducted a behavioral nutrition and exercise program since 2003. the name of the program is teens, empowerment, exercise, education, nutrition (teeen) program. we meet once a month on a saturday afternoon for four hours. during this time we cover: registration (monitoring of sedentary activities and liquid choices; motivational interview, exercise testing); exercise; educational interactive lectures; didactic games and projects. we have noticed that participants seem to have a better quality of life after participating in the program compared to baseline. we would like to objectively quantify this subjective finding. we will be using the pediatric quality of life inventory version 4.0 (pedsql(tm)4.0) questionnaire which has been validated in the pediatric population. we will have an intervention and a control group. both participants and their caretakers will be given a questionnaire at the beginning and at the end of the study.

Eligibility criteria:
inclusion criteria: * ages 10-20 * bmi greater or equal to 85%

Keywords: bmi quality of life
safety of intravenous milrinone for the treatment of subarachnoid hemorrhage-induced vasospasm

Conditions: Cerebral Vasospasm; Subarachnoid Hemorrhage

Summary: the aim of this study is to evaluate the tolerance of intravenous milrinone combined to the current standard treatment for cerebral vasospasm following subarachnoid hemorrhage. assessment of iv milrinone safety in this setting is mandatory before the conduction of a large study assessing its effectiveness.

the aim of this prospective observational study is to evaluate the hemodynamic tolerance of intravenous milrinone for the treatment of arterial vasospasm following subarachnoid hemorrhage. intravenous milrinone is part of our standard care protocol for the management of cerebral vasospasm in association with nimodipine (intravenous or enteral route) and high arterial blood pressure (mean arterial pressure of 100-120 mmhg, spontaneously or induced by volume expansion and norepinephrine). all patients of our icu who were diagnosed with cerebral arterial vasospasm during the few days following a subarachnoid hemorrhage will be included.

Eligibility criteria:
inclusion criteria: * subjects 18 years * hospitalized in our intensive care unit * subarachnoid hemorrhage proven on ct angiogram * cerebral vasospasm proven on ct angiogram exclusion criteria: * pregnant women * minor * major under guardianship

Keywords: cerebral vasospasm subarachnoid hemorrhage milrinone hemodynamic tolerance
aerobic, resistance, inspiratory training outcomes in heart failure

Conditions: Heart Failure

Summary: this study investigates the effects of aerobic, resistance, inspiratory training modalities outcomes in functional capacity and quality of life of heart failure (hf) patients, aiming for the 'optimum' (greek, αριστος=aristos) training program for hf patients.

heart failure is a clinical syndrome characterized by symptoms of dyspnea, exercise intolerance and decreased quality of life. a weakness in both inspiratory and peripheral muscles is also reported. aerobic training (at) improves the functional status of hf patients (level of evidence ia). additional benefits of inspiratory muscle training (imt) and/or resistance training (rt) when combined with aerobic training (at) in hf symptoms have also been found. four exercise groups will be studied in order to identify the optimum exercise program i. aerobic-resistance-inspiratory training (aris) group ii. aerobic training-resistance training (at/rt) group iii. aerobic training-inspiratory muscle training (at/imt) group iv. aerobic training (at) group

Eligibility criteria:
inclusion criteria: * chronic heart failure (from new york heart association (nyha) functional class ii to nyha iii) * left ventricular ejection fraction below or equal to 35% exclusion criteria: * uncontrolled arrhythmia * pulmonary oedema or pulmonary congestion in the last 30 days * cognitive, neurological or orthopaedic limitations * respiratory infection during 30 days before the start of the study * pulmonary limitations (e.g copd)

Keywords: rehabilitation exercise training